Christopher R. Behrens

922 total citations
12 papers, 615 citations indexed

About

Christopher R. Behrens is a scholar working on Radiology, Nuclear Medicine and Imaging, Molecular Biology and Oncology. According to data from OpenAlex, Christopher R. Behrens has authored 12 papers receiving a total of 615 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Radiology, Nuclear Medicine and Imaging, 5 papers in Molecular Biology and 4 papers in Oncology. Recurrent topics in Christopher R. Behrens's work include Monoclonal and Polyclonal Antibodies Research (7 papers), Click Chemistry and Applications (3 papers) and Multiple Myeloma Research and Treatments (3 papers). Christopher R. Behrens is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (7 papers), Click Chemistry and Applications (3 papers) and Multiple Myeloma Research and Treatments (3 papers). Christopher R. Behrens collaborates with scholars based in United States. Christopher R. Behrens's co-authors include Bin Liu, Matthew B. Francis, Su Yang, Daniel W. Sherbenou, Byron Hann, Michelle E. Farkas, Jeffrey L. Wolf, Thomas G. Martin, Gary J. Tong and James P. O’Neil and has published in prestigious journals such as Journal of the American Chemical Society, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Christopher R. Behrens

12 papers receiving 599 citations

Peers

Christopher R. Behrens
Timothy M. Jacobs United States
Anne C.E. Moor Netherlands
Rajesh Vij United States
Binyam Bezabeh United States
Mark P. O'Connell United States
Igor Fisch Switzerland
Joost A. Kolkman Netherlands
Christopher R. Behrens
Citations per year, relative to Christopher R. Behrens Christopher R. Behrens (= 1×) peers Torsten Hechler

Countries citing papers authored by Christopher R. Behrens

Since Specialization
Citations

This map shows the geographic impact of Christopher R. Behrens's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher R. Behrens with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher R. Behrens more than expected).

Fields of papers citing papers by Christopher R. Behrens

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher R. Behrens. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher R. Behrens. The network helps show where Christopher R. Behrens may publish in the future.

Co-authorship network of co-authors of Christopher R. Behrens

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher R. Behrens. A scholar is included among the top collaborators of Christopher R. Behrens based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher R. Behrens. Christopher R. Behrens is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
2.
Yang, Su, et al.. (2020). ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen. Cancer Research. 80(20). 4552–4564. 22 indexed citations
3.
Sherbenou, Daniel W., Su Yang, Christopher R. Behrens, et al.. (2020). Potent Activity of an Anti-ICAM1 Antibody–Drug Conjugate against Multiple Myeloma. Clinical Cancer Research. 26(22). 6028–6038. 18 indexed citations
4.
Yang, Su, Yue Liu, Christopher R. Behrens, et al.. (2018). Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 3(17). 56 indexed citations
5.
Sherbenou, Daniel W., Blake T. Aftab, Su Yang, et al.. (2016). Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. Journal of Clinical Investigation. 126(12). 4640–4653. 83 indexed citations
6.
Sherbenou, Daniel W., Christopher R. Behrens, Su Yang, et al.. (2014). The development of potential antibody-based therapies for myeloma. Blood Reviews. 29(2). 81–91. 34 indexed citations
7.
Behrens, Christopher R. & Bin Liu. (2013). Methods for site-specific drug conjugation to antibodies. mAbs. 6(1). 46–53. 142 indexed citations
8.
Netirojjanakul, Chawita, et al.. (2012). Synthetically modified Fc domains as building blocks for immunotherapy applications. Chemical Science. 4(1). 266–272. 23 indexed citations
9.
Farkas, Michelle E., Ioana L. Aanei, Christopher R. Behrens, et al.. (2012). PET Imaging and Biodistribution of Chemically Modified Bacteriophage MS2. Molecular Pharmaceutics. 10(1). 69–76. 76 indexed citations
10.
Behrens, Christopher R., et al.. (2011). Rapid Chemoselective Bioconjugation through Oxidative Coupling of Anilines and Aminophenols. Journal of the American Chemical Society. 133(41). 16398–16401. 53 indexed citations
11.
Hatzios, Stavroula K., Michael W. Schelle, Cynthia M. Holsclaw, et al.. (2009). PapA3 Is an Acyltransferase Required for Polyacyltrehalose Biosynthesis in Mycobacterium tuberculosis. Journal of Biological Chemistry. 284(19). 12745–12751. 53 indexed citations
12.
Leavell, Michael D., Petr Novák, Christopher R. Behrens, Joseph S. Schoeniger, & Gary Kruppa. (2004). Strategy for selective chemical cross-linking of tyrosine and lysine residues. Journal of the American Society for Mass Spectrometry. 15(11). 1604–1611. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026